Evidence map›Paper›PMID 34879180›Full record

ArticleAdvanced healthcare materials2022

Engineered Cell-Derived Vesicles Displaying Targeting Peptide and Functionalized with Nanocarriers for Therapeutic microRNA Delivery to Triple-Negative Breast Cancer in Mice.

Rajendran Jc Bose, Uday Sukumar Kumar, Fernando Garcia-Marques, Yitian Zeng, Frezghi Habte, Jason R McCarthy, Sharon Pitteri, Tarik F Massoud, Ramasamy Paulmurugan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Therapeutic potential of extracellular vesicles for treating human pregnancy disorders.Extracellular vesicles and circulating nucleic acids · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rajendran Jc BoseMolecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.
Uday Sukumar KumarMolecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.
Fernando Garcia-MarquesMolecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.
Yitian ZengDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, 94305-4034, USA.
Frezghi HabteMolecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.
Jason R McCarthyBiomedical and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Sharon PitteriCanary Center at Stanford for Cancer Early Detection, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.
Tarik F MassoudMolecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.
Ramasamy PaulmuruganMolecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, School of Medicine, Stanford University, Stanford, CA, 94305-5427, USA.ORCID 0000-0001-7155-4738
Stanford University · USMasonic Medical Research Laboratory · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Therapeutic miRNA Modulation of Hepatocellular Carcinoma Using Ultrasound Guided Drug DeliveryR01CA209888 · NCI · STANFORD UNIVERSITY · PI DAHL, JEREMY, PAULMURUGAN, RAMASAMY · 2017 to 2021
$3.1M
3D Passive Cavitation Imaging-Guided Therapeutic Delivery of MicroRNA into CancerR21EB022298 · NIBIB · STANFORD UNIVERSITY · PI PAULMURUGAN, RAMASAMY · 2016 to 2017
$441k
Celigo S Imaging Cytometer (200-BFFL-S)S10OD023518 · OD · STANFORD UNIVERSITY · PI PAULMURUGAN, RAMASAMY · 2018 to 2018
$174k
NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA209888NIBIB NIH HHS R21 EB022298NIH HHS S10 OD023518
6 · The paper itself

Abstract

Polymeric nanocarriers (PNCs) can be used to deliver therapeutic microRNAs (miRNAs) to solid cancers. However, the ability of these nanocarriers to specifically target tumors remains a challenge. Alternatively, extracellular vesicles (EVs) derived from tumor cells show homotypic affinity to parent cells, but loading sufficient amounts of miRNAs into EVs is difficult. Here, it is investigated whether uPAR-targeted delivery of nanococktails containing PNCs loaded with therapeutic antimiRNAs, and coated with uPA engineered extracellular vesicles (uPA-eEVs) can elicit synergistic antitumor responses. The uPA-eEVs coating on PNCs increases natural tumor targeting affinities, thereby enhancing the antitumor activity of antimiRNA nanococktails. The systemic administration of uPA-eEV-PNCs nanococktail shows a robust tumor tropism, which significantly enhances the combinational antitumor effects of antimiRNA-21 and antimiRNA-10b, and leads to significant tumor regression and extension of progression free survival for syngeneic 4T1 tumor-bearing mice. In addition, the uPA-eEV-PNCs-antimiRNAs nanococktail plus low dose doxorubicin results in a synergistic antitumor effect as evidenced by inhibition of tumor growth, reduction of lung metastases, and extension of survival of 4T1 tumor-bearing mice. The targeted combinational nanococktail strategy could be readily translated to the clinical setting by using autologous cancer cells that have flexibility for ex vivo expansion and genetic engineering.

Indexed as

Extracellular VesiclesMicroRNAsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDoxorubicinHumansMicePeptidesDoxorubicinMicroRNAsPeptidesantisense miRNAcell free cancer therapeuticsengineered nanococktailstargeted combinational cancer therapytriple-negative breast cancer

Identifiers

PMID34879180
PMCPMC8891081
OpenAlexW4200610391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.